stella
beta
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome — Stella
Recruiting
Back to Primary Sjogren's Syndrome trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Tongji Hospital of Tongji University, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov